Epileptic seizures are unpredictable, often occurring in clusters followed by seizure-free periods lasting weeks or months. Diagnosing and characterizing epilepsy depends on capturing these sporadic seizures during electroencephalography (EEG) monitoring.

Researchers from Duke’s Preston Robert Tisch Brain Tumor Center have found that a therapy targeting the epidermal growth factor receptor (EGFR) can be safely delivered directly into recurrent glioblastomas and may improve patient

Duke researchers are leading a phase I clinical trial to evaluate a new experimental treatment for glioblastoma, one of the most aggressive and deadly forms of

Aden Haskell-Mendoza, MD, is the recipient of Glioblastoma Foundation’s 2026 Neil Peart Neurosurgery Resident Re